Stockreport

TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO [Yahoo! Finance]

TransCode Therapeutics, Inc.  (RNAZ) 
PDF RECIST data with apparent stable disease lasting over 4 months in 44% of patients (7 out of 16) Safety and durability profile consistent with known mechanism of actio [Read more]